HomeCompareIMXCF vs ABBV

IMXCF vs ABBV: Dividend Comparison 2026

IMXCF yields 216.17% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $16.8K in total portfolio value· pulled ahead in Year 10
10 years
IMXCF
IMXCF
● Live price
216.17%
Share price
$0.93
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$85.6K
Annual income
$91.74
Full IMXCF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — IMXCF vs ABBV

📍 ABBV pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIMXCFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IMXCF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IMXCF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IMXCF
Annual income on $10K today (after 15% tax)
$18,374.41/yr
After 10yr DRIP, annual income (after tax)
$77.98/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,978.03/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IMXCF + ABBV for your $10,000?

IMXCF: 50%ABBV: 50%
100% ABBV50/50100% IMXCF
Portfolio after 10yr
$94.0K
Annual income
$12,431.75/yr
Blended yield
13.23%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

IMXCF
No analyst data
Altman Z
5.2
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IMXCF buys
0
ABBV buys
0
No recent congressional trades found for IMXCF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIMXCFABBV
Forward yield216.17%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$85.6K$102.3K
Annual income after 10y$91.74$24,771.77
Total dividends collected$40.0K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: IMXCF vs ABBV ($10,000, DRIP)

YearIMXCF PortfolioIMXCF Income/yrABBV PortfolioABBV Income/yrGap
1$21,508$10,808.47$11,550$430.00+$10.0KIMXCF
2$33,877$10,863.26$13,472$627.96+$20.4KIMXCF
3$44,244$7,995.51$15,906$926.08+$28.3KIMXCF
4$52,221$4,879.55$19,071$1,382.55+$33.1KIMXCF
5$58,568$2,691.25$23,302$2,095.81+$35.3KIMXCF
6$64,078$1,410.43$29,150$3,237.93+$34.9KIMXCF
7$69,284$721.09$37,536$5,121.41+$31.7KIMXCF
8$74,499$364.34$50,079$8,338.38+$24.4KIMXCF
9$79,897$183.06$69,753$14,065.80+$10.1KIMXCF
10← crossover$85,581$91.74$102,337$24,771.77$16.8KABBV

IMXCF vs ABBV: Complete Analysis 2026

IMXCFStock

IMAX China Holding, Inc., an investment holding company, provides digital and film-based motion picture technologies in the People's Republic of China, Hong Kong, Macau, and Taiwan. It operates through three groups: IMAX Technology Network, IMAX Technology Sales and Maintenance, and New Business Initiatives and Other. The company engages in the digital re-mastering of Hollywood and Chinese language films into the IMAX format through a proprietary IMAX DMR conversion process and the exhibition of these films on the IMAX theatre network. It also designs, procures, and provides digital theatre systems at its exhibitor partners' movie theatres, as well as offers related project management, maintenance, and aftermarket services. In addition, the company provides technical research and development, consulting, service, training and marketing services for theatre systems and multimedia technology; and photographic equipment, virtual reality display equipment and related software and hardware, as well as engages in the provision of after-sales services, including installation. Further, it is involved in the wholesale, import, leasing, installing, maintenance, and repairing of movie theatre machinery, equipment, systems, photographic equipment, virtual reality display equipment, and related software; and research and development of software and hardware. Additionally, the company offers gift, handicraft, stationery commodity, clothing and apparel, and electronic products; and creative and conference, business consultation, and culture and art exchange and planning services, as well as operates ticket and publishing agency. It also engages in the design and production of advertising. The company was incorporated in 2010 and is headquartered in Shanghai, China. IMAX China Holding, Inc. is a subsidiary of Imax (Barbados) Holdings, Inc.

Full IMXCF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this IMXCF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IMXCF vs SCHDIMXCF vs JEPIIMXCF vs OIMXCF vs KOIMXCF vs MAINIMXCF vs JNJIMXCF vs MRKIMXCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.